This editorial refers to 'Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries' † , by Y. Odaka et al., on page 489.
This editorial refers to 'Plasma concentration of serotonin is a novel biomarker for coronary microvascular dysfunction in patients with suspected angina and unobstructive coronary arteries' † , by Y. Odaka et al., on page 489.
In this issue, Shimokawa and colleagues beautifully propose that the plasma concentration of serotonin [5-hydroxytryptamine (5HT)] can be accepted as a novel biomarker for coronary microvascular dysfunction in patients with suspected angina without angiographic evidence of anatomical obstruction of the coronary arteries. 1 They based their proposal on measurements of the level of the monoamine in blood withdrawn at the left coronary ostium (and thus entering the left coronary artery) prior to performing a conventional acetylcholine provocation test, on the one hand, and the diagnosis of coronary microvascular dysfunction (in the absence of or prior to vasospastic responses to acetylcholine) by estimation of the amount of lactate extraction across the coronary circulation, on the other hand. Their statistical analysis also yields a positive correlation between the plasma concentration of serotonin and an accepted marker (baseline TIMI frame count) of coronary vascular resistance. In a further elegant statistical scrutinizing of their data by a classification and regression tree (CART) and multivariable analysis, the authors determined the cut-off point concentration (10 mmol/L) of serotonin that appears to be the real predictor of coronary microvascular dysfunction, in the absence of vasospasm or coronary obstruction. A major strength of their study is that they measure the level of the monoamine at the entrance of the coronary circulation, which automatically answers the chicken-or-egg question and permits the acceptance of serotonin as a causal factor of the microvascular dysfunction when they diagnose it. Hence, one can only accept their interpretation and welcome the nearly three-quarters of a century old serotonin as a predictor of such dysfunction. However, the authors' enthusiasm in proposing their method as 'non-invasive' should be tempered since it is based on rather aggressive measurements in blood harvested at the coronary ostium, not paralleled by similar determinations in peripheral venous blood. If the proposal to link the arterial plasma concentration of serotonin to coronary vascular dysfunction is novel, the concept that serotonin is related to coronary disease obviously is not, as the authors recognize. Thus, almost 30 years ago, plasma withdrawn from the coronary sinus from patients with coronary disease was shown to possess vasoconstrictor properties attributable to serotonin, 2 and the association of increased levels of the monoamine and such disease has been comfirmed repeatedly. [3] [4] [5] [6] Odaka and colleagues 1 also mention hypertension as an important risk factor for coronary microvascular dysfunction, and, certainly in animals, hypertension exacerbates the vasoconstrictor effect of serotonin at the coronary microvascular level, 7 implying that the underlying pathological state of the vascular wall is an important determinant of the responsiveness to the monoamine. Under physiological conditions, if serotonin is present in the blood (whether exogenously added or released from aggregating platelets), the first vascular layer that it will reach are the endothelial cells, on the membrane of which it binds to 5HT 1D receptors, linked through pertussis toxin-sensitive G i -proteins to the activation of endothelial nitric oxide synthase (eNOS); the nitric oxide (NO) produced by the latter enzyme will diffuse towards both the lumen (inhibiting platelet aggregation) and the underlying vascular smooth muscle (relaxing them mainly by activating soluble guanylyl cyclase which produces the vasodilator cGMP) ( Figure 1 ). 8, 9 The tight junctions between the endothelial cells prevent the free diffusion of serotonin to the underlying vascular smooth muscle cells. In addition, the serotonin transporter(s) of the endothelial cells take up the free monoamine which is degraded intracellularly by monoamine oxidase into the inactive metabolite 5-hydroxyindole acetic acid; 10 this degradation normally prevents the monoamine from traversing the endothelium and thus reaching the underlying vascular smooth muscle cells ( Figure 1 ). Hence, in healthy blood vessels under physiological conditions, intraluminal serotonin presumably only causes vasodilatation. 11 However, the picture changes when endothelial cells become dysfunctional as is the case in obesity, diabetes, hypertension, and atherosclerosis. 8, 9 For example, when endothelial cells regenerate after angioplasty, they lose the 5HT 1D -initiated, G i -protein-linked, eNOS-mediated vasodilator response to serotonin, a loss exacerbated by a high fat diet ( Figure 1) . Figure 1) . Thus, intraluminal serotonin can reach the media, activate 5HT 2 receptors on the vascular smooth muscle cells which initiate the entry of activator calcium, and the monoamine becomes the vasoconstrictor, explaining the occurrence of coronary microvascular dysfunction demonstrated by Okada and colleagues 1 ( Figure 1) .
Actually, even if serotonin were to release endothelial NO, in certain pathological situations this may not lead to vasodilatation, but rather the contrary. Indeed, we have known for a long time that, at least in large coronary arteries, hypoxia considerably augments the constrictor response to serotonin. 13 Such hypoxic augmentations of vasoconstrictor responses in coronary arteries are endothelium dependent and depend on the production of NO by eNOS and the subsequent activation of soluble guanylyl cyclase; however, the activity of the latter enzyme is biased by hypoxia and leads to the production of the vasoconstrictor cIMP rather than its beneficial canonical product, cGMP. 14, 15 Thus one can envisage a scenario whereby, in ischaemic myocardial tissue, if the endothelial cells respond normally (or in a reduced manner because of G i -coupling dysfunction) to 5HT 1D activation by producing NO, the latter would activate the biased soluble guanylyl cyclase, thus inceasing the production of cIMP and hence induce vasoconstriction ( Figure 1) . Serotonin is certainly a cardiovascular old-timer. One of its discoverers, Dr Irvine Page, felt that he originally had considered its presence in the plasma to be but a complication preventing the proper assessment of the role of angiotensin II and wrote that it was one of the substances in the body that are a nuisance to one person (obviously he thought of himself) but give tenure to others (thinking mainly of certain neuroscientists). 16 Ignoring that comment, during the last 50 years, we and others have tried to define the role of serotonin in cardiovascular homeostasis beyond its function as the optimal amplifier of platelet aggregation. In doing so, one obviously keeps rediscovering the wheel: indeed serotonin can be a potent vasoconstrictor and indeed it may (or may not) be causally involved in the abnormal responsiveness characterizing certain vascular diseases (e.g hypertension and coronary insufficiency). The article by Okada and colleagues 1 certainly provides a new shiny cover for this old wheel. . . From the above, one may understand why the occurrence of vasoconstrictor responses to plasma serotonin must require an appropriate stage of local endothelial dysfunction and/or possibly abnormal contractile responsiveness of vascular smooth muscle under hypoxic conditions; this may explain why high plasma levels of the monoamine do not cause coronary microvascular dysfunction in all cases. However, we are still at loss to answer the main question: why does the arterial serum contain >10 mmol/L serotonin when it presents itself at the coronary ostia in certain patients?
Conflicts of interest: none declared. Figure 1 Fate of intraluminal serotonin in the normal and dysfunctional blood vessel wall explaining the occurrence of coronary microvascular dysfunction. Top: under normal physiological conditions, the serotonin (5HT), presumably released from aggregating platelets, acts mainly on 5HT 1D -serotonergic receptors of the endothelial cell membrane. These are coupled through pertussis toxin-sensitive G i -proteins (Gi) to the activation of endothelial nitric oxide synthase (eNOS). The resulting production of nitric oxide (NO) exerts a negative feedback on platelet aggregation and also diffuses to the underlying vascular smooth muscle where it activates soluble guanylyl cyclase (sGC) resulting in the formation of the strongly vasodilating cyclic guanosine monophosphate (cGMP) which causes relaxation. The intraluminal serotonin is captured and transferred intracellularly by the serotonin transporter (SERT) of the endothelial cells where it is degraded by monoamine oxidase (MAO A ) to the inactive metabolite 5-hydroxyindole acetic acid (5HIAA). In addition, the tight junctions (..) between the endothelial cells prevent the monoamine from diffusing freely to the underlying vascular smooth muscle cells. Thus, the intraluminal serotonin causes mainly vasodilatation. Bottom: if the endothelial cells become dysfunctional, they progressively lose the G i -coupling between the 5HT 1D receptors and eNOS, and less NO is formed, with a resulting reduced production of the vasodilator cGMP. If the tissue is hypoxic, the activity of sGC becomes biased, with the production of the vasoconstrictor cyclic inosine monophosphate (cIMP) which favours vasoconstriction. If the activity of the serotonin transporter and/or MAO is reduced, serotonin can traverse the endothelial cell and reach the vascular smooth muscle, a process facilitated if the barrier function of the endothelial cells is also impaired. The serotonin reaching the vascular smooth muscle cells activates the 5HT 2 -serotonergic receptor which opens calcium (Ca 2þ ) channels and initiates the contractile process. Thus intraluminal serotonin becomes a vasoconstrictor. , augmented activity/production; ٜ; , inhibition; dotted line, reduced inhibition/production; jagged line, dysfunctional coupling. (Courtesy of Dr Susan W. Leung.)
